Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
…, O Dissanayake, N Gamalath… - Immunity …, 2022 - Wiley Online Library
Background To determine the kinetics and persistence of immune responses following the
Sinopharm/BBIBP‐CorV, we investigated immune responses in a cohort of Sri Lankan …
Sinopharm/BBIBP‐CorV, we investigated immune responses in a cohort of Sri Lankan …
Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka
…, S Dayarathne, O Dissanayake, N Gamalath… - MedRxiv, 2021 - medrxiv.org
Background As there are limited data of the immunogenicity of the Sinopharm/BBIBP-CorV
in different populations, antibody responses against different SARS-CoV-2 variants of …
in different populations, antibody responses against different SARS-CoV-2 variants of …
Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
…, S Dayarathne, O Dissanayake, N Gamalath… - MedRxiv, 2021 - medrxiv.org
Background To determine the kinetics and persistence of immune responses following the
Sinopharm/BBIBP-CorV, we investigated immune responses in a cohort of Sri Lankan …
Sinopharm/BBIBP-CorV, we investigated immune responses in a cohort of Sri Lankan …
Immune responses to Sinopharm/BBIBP‐CorV in individuals in Sri Lanka
…, S Dayarathne, O Dissanayake, N Gamalath… - …, 2022 - Wiley Online Library
As there are limited data of the immunogenicity of the Sinopharm/BBIBP‐CorV in different
populations, antibody responses against different SARS‐CoV‐2 variants of concern and T cell …
populations, antibody responses against different SARS‐CoV‐2 variants of concern and T cell …
[HTML][HTML] Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac)
…, S Dayarathne, O Dissanayake, N Gamalath… - Scientific Reports, 2022 - nature.com
As the first dose of Gam-COVID-Vac, is currently used as a single dose vaccine in some
countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% …
countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% …
Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals
…, O Dissanayake, N Gamalath… - Immunity …, 2022 - Wiley Online Library
Background To understand the kinetics of immune responses with different dosing gaps of
the AZD1222 vaccine, we compared antibody and T cell responses in two cohorts with two …
the AZD1222 vaccine, we compared antibody and T cell responses in two cohorts with two …
[HTML][HTML] Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka
…, H Kuruppu, O Dissanayake, N Gamalath… - PLOS global public …, 2022 - journals.plos.org
Background There are limited data regarding the safety and immunogenicity of the
Sinopharm/BBIBP-CorV vaccine in pregnancy. Therefore, we sought to investigate the antibody …
Sinopharm/BBIBP-CorV vaccine in pregnancy. Therefore, we sought to investigate the antibody …
Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka
…, D Ekanayake, J Jayamali, N Gamalath… - The Journal of …, 2021 - journals.aai.org
Due to limited access to vaccines, many countries have only administered a single dose of
the AZD1222, whereas the dosage intervals have increased≥ 4 wk. We sought to investigate …
the AZD1222, whereas the dosage intervals have increased≥ 4 wk. We sought to investigate …
Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka (preprint)
…, S Dayarathne, O Dissanayake, N Gamalath… - 2021 - pesquisa.bvsalud.org
Background As there are limited data of the immunogenicity of the Sinopharm/BBIBP-CorV
in different populations, antibody responses against different SARS-CoV-2 variants of …
in different populations, antibody responses against different SARS-CoV-2 variants of …
Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac)
…, S Dayarathne, O Dissanayaka, N Gamalath… - 2021 - researchsquare.com
As the first dose of Gam-COVID-Vac, is currently used as a single dose vaccine in some
countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% …
countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% …